Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
Nov 15, 2026, 23:44

Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement

Pablo César Spada, Head of Cardiology at Morón Municipal Hospital, shared a post on LinkedIn:

“Prevention of Venous Thromboembolism After Total Hip or Knee Replacement

Pellegrini VD Jr. et al. | NEJM | November 12, 2026

This is a large, randomized, comparative-effectiveness trial evaluating three strategies for preventing venous thromboembolism (VTE) after elective total hip or knee arthroplasty.

The central clinical question is:

Can aspirin provide similar protection against postoperative VTE as warfarin or rivaroxaban, without increasing clinically important bleeding?

Why is this trial important?

Total hip and knee replacement are associated with an increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Pharmacological thromboprophylaxis is standard practice, but the optimal agent remains controversial.

  • Aspirin: inexpensive, convenient, and generally associated with a low bleeding risk.
  • Warfarin: effective anticoagulant, but requires INR monitoring and dose adjustments.
  • Rivaroxaban: direct factor Xa inhibitor with predictable anticoagulation and no routine INR monitoring.

Previous comparisons have produced conflicting results, particularly regarding the effectiveness of aspirin.

Clinical interpretation

The PEPPER trial suggests that aspirin cannot be assumed to provide equivalent effectiveness to anticoagulants after hip or knee replacement.

However, the absolute differences were small, and the safety findings favor careful individualization.

For clinical practice, I would emphasize three points:

Rivaroxaban had the lowest observed rate of the effectiveness endpoint.

Aspirin had the lowest observed rate of the composite safety endpoint.

Selection should consider baseline VTE risk, bleeding risk, wound complications, and patient characteristics.

One important limitation is that the safety composite is broader than major bleeding alone. Therefore, its results should not be interpreted as major bleeding rates.

PEPPER does not establish aspirin as noninferior to rivaroxaban or warfarin for preventing death or symptomatic VTE after hip or knee arthroplasty.

Conversely, neither anticoagulant demonstrated noninferiority to aspirin for the composite safety outcome.

For a cardiology journal club, the most interesting question is whether an absolute difference of approximately 0.3 percentage points in effectiveness justifies routine anticoagulation when safety events may increase.”

Pablo César Spada

Stay updated with Hemostasis Today.